The recently approved C3 inhibitor pegcetacoplan, designed to block extravascular hemolysis, has been shown to improve anemia and hemolytic laboratory markers to a greater extent than eculizumab in patients with PNH [13]. Here, C3 is linked to anemia (phenotype).